MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]

Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit<br />Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,<br />discuss several important presentations from the recent 2021 ASH meeting.<br />They focus on the new IPSS-M classification, discuss the approach to the<br />MDS patient who is currently defined by IPSS/R as belonging to the /lower-<br />risk group but in fact the disease behaves like a higher-risk. Finally, they<br />discuss issues regarding the treatment of patients with HR-MDS: What can be<br />added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition<br />and more…